Literature DB >> 23465509

Caspr2 antibodies in limbic encephalitis with cerebellar ataxia, dyskinesias and myoclonus.

Bettina Balint1, Jens Uwe Regula, Sven Jarius, Brigitte Wildemann.   

Abstract

Here we report on a case of contactin-associated protein-2 (Caspr2) antibody positive but voltage gated potassium channel (VGKC) antibody negative limbic encephalitis associated with cerebellar ataxia, myoclonus and dyskinesias with favorable response to immunotherapy. This case underlines the importance of Caspr2-specific antibody testing and demonstrates that Caspr2 antibodies are associated with a broader clinical spectrum than hitherto described.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23465509     DOI: 10.1016/j.jns.2013.01.040

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  Autoimmune epilepsies.

Authors:  Christian G Bien; Jan Bauer
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

2.  Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity-syndrome of parkinsonism and ataxia.

Authors:  Sudheeran Kannoth; Vivek Nambiar; Siby Gopinath; Anandkumar Anandakuttan; Annamma Mathai; Parvathy Kanjiramana Rajan
Journal:  Neurol Sci       Date:  2017-12-20       Impact factor: 3.307

Review 3.  Subcellular patterning: axonal domains with specialized structure and function.

Authors:  Elizabeth A Normand; Matthew N Rasband
Journal:  Dev Cell       Date:  2015-02-23       Impact factor: 12.270

Review 4.  Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Nicolás Lundahl Ciano-Petersen; Macarena Villagrán-García; Bastien Joubert; Jérôme Honnorat
Journal:  Cerebellum       Date:  2022-01-12       Impact factor: 3.648

5.  Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia.

Authors:  Valentina Damato; Claudia Papi; Gregorio Spagni; Amelia Evoli; Gabriella Silvestri; Gianvito Masi; Eleonora Sabatelli; Lucia Campetella; Andrew McKeon; Francesca Andreetta; Vittorio Riso; Gabriele Monte; Marco Luigetti; Guido Primiano; Paolo Calabresi; Raffaele Iorio
Journal:  Eur J Neurol       Date:  2021-11-09       Impact factor: 6.288

6.  The clinical spectrum of Caspr2 antibody-associated disease.

Authors:  Agnes van Sonderen; Helena Ariño; Mar Petit-Pedrol; Frank Leypoldt; Peter Körtvélyessy; Klaus-Peter Wandinger; Eric Lancaster; Paul W Wirtz; Marco W J Schreurs; Peter A E Sillevis Smitt; Francesc Graus; Josep Dalmau; Maarten J Titulaer
Journal:  Neurology       Date:  2016-07-01       Impact factor: 9.910

Review 7.  'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

Review 8.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

9.  Eyelid tremor in a patient with anti-caspr2 antibody-related encephalitis.

Authors:  Shuichi Ueno; Makito Hirano; Hikaru Sakamoto; Susumu Kusunoki; Yusaku Nakamura
Journal:  Case Rep Neurol       Date:  2014-08-27

10.  Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis.

Authors:  Bastien Joubert; Florent Gobert; Laure Thomas; Margaux Saint-Martin; Virginie Desestret; Philippe Convers; Véronique Rogemond; Géraldine Picard; François Ducray; Dimitri Psimaras; Jean-Christophe Antoine; Jean-Yves Delattre; Jérôme Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.